Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds-News

13G Filing: Park West Asset Management and Eagle Pharmaceuticals, Inc. (EGRX)

Published on January 22, 2016 at 3:00 pm by Meena Krishnamsetty in Hedge Funds, News

Peter Park‘s Park West Asset Management has recently reported its position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) through a 13G filing with the Securities and Exchange Commission. According to the filing, Park West owns 690,000 shares of Eagle Pharmaceutical and the stake, which is passive by nature, amasses 4.4% of the company’s outstanding common stock.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Park West Asset Management LLC 690,000 0 690,000 0 690,000 4.4%
Peter S. Park 690,000 0 690,000 0 690,000 4.4%

Follow Peter S. Park's Park West Asset Management

Page 1 of 9 SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
EAGLE PHARMACEUTICALS, INC.
(Name of Issuer)
 
COMMON STOCK, $0.001 PAR VALUE PER SHARE
(Title of Class of Securities)
 
269796108
(CUSIP Number)
 
December 31, 2015
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
o  Rule 13d-1(b)
x Rule 13d-1(c)
o  Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 2 of 9 SEC Filing

CUSIP No. 269796108
 
(1)
 
Names of Reporting Persons
Park West Asset Management LLC
 
(2)
  
Check the Appropriate Box if a Member of a Group (See Instructions) 
 
(a) ¨
(b) ¨
 
(3)
 
SEC Use Only
 
(4)
 
Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by
Each Reporting Person With:
(5) Sole Voting Power                                                               
   690,000*
 
(6) Shared Voting Power                        
  0
 
(7) Sole Dispositive Power               
   690,000*
 
(8) Shared Dispositive Power                        
  0
 
(9)
 
Aggregate Amount Beneficially Owned by Each Reporting Person
690,000*
 
(10)
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):             ¨
 
(11)
 
Percent of Class Represented by Amount in Row (9)
4.4%*
 
(12)
 
Type of Reporting Person (See Instructions)
IA
* Beneficial ownership percentage is based upon 15,589,844 shares of common stock, $0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued and outstanding as of November 10, 2015, based on information reported by the Company in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 12, 2015.  Park West Asset Management LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”) is the sole member and manager of PWAM.  As of December 31, 2015, PWIMF held 606,247 shares of Common Stock and PWPI held   83,753 shares of Common Stock of the Company.  As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed to beneficially own the  690,000 shares of Common Stock held in the aggregate by the PW Funds, or 4.4% of the shares of Common Stock deemed to be issued and outstanding as of December 31, 2015.

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 3 of 9 SEC Filing

CUSIP No. 269796108
 
(1)
 
Names of Reporting Persons
Peter S. Park
 
(2)
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
(a) ¨
(b) ¨
 
(3)
 
SEC Use Only
 
(4)
 
Citizenship or Place of Organization
United States of America
Number of Shares Beneficially Owned by
Each Reporting Person With:
(5) Sole Voting Power
 690,000*
 
(6) Shared Voting Power
 0
 
(7) Sole Dispositive Power
 690,000*
 
(8) Shared Dispositive Power
 0
 
(9)
 
Aggregate Amount Beneficially Owned by Each Reporting Person
690,000*
 
(10)
 
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):             ¨
 
(11)
 
Percent of Class Represented by Amount in Row (9)
4.4%*
 
(12)
 
Type of Reporting Person (See Instructions)
IN
* Beneficial ownership percentage is based upon 15,589,844 shares of common stock, $0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued and outstanding as of November 10, 2015, based on information reported by the Company in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 12, 2015.  Park West Asset Management LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”) is the sole member and manager of PWAM.  As of December 31, 2015, PWIMF held 606,247 shares of Common Stock and PWPI held   83,753 shares of Common Stock of the Company.  As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed to beneficially own the  690,000 shares of Common Stock held in the aggregate by the PW Funds, or 4.4% of the shares of Common Stock deemed to be issued and outstanding as of December 31, 2015.

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 4 of 9 SEC Filing

Item 1(a).  Name Of Issuer: Eagle Pharmaceuticals, Inc. (the “Company”)
Item 1(b).  Address of Issuer’s Principal Executive Offices.
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ 07677
Item 2(a).  Name of Person Filing.
This report on Schedule 13G (this “Schedule 13G”), is being jointly filed by (i) Park West Asset Management LLC (“PWAM”), a Delaware limited liability company and the investment manager to (a) Park West Investors Master Fund, Limited (“PWIMF”), a Cayman Islands exempted company that is the holder of 606,247 shares of common stock, $0.001 par value per share (“Common Stock”) of the Company reported on this Schedule 13G, and (b) Park West Partners International, Limited (“PWPI” and, collectively with PWIMF, the “PW Funds”), a Cayman Islands exempted company that is the holder of 83,753 shares of Common Stock reported on this Schedule 13G; and (ii) Peter S. Park, as the sole member and manager of PWAM (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”).
The 690,000 shares of Common Stock held in the aggregate by the PW Funds, which constitute 4.4% of the shares of Common Stock deemed to be outstanding as of December 31, 2015, may be deemed to be beneficially owned (x) indirectly by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.
Item 2(b).  Address of Principal Business Office or, if None, Residence.
The address for the Reporting Persons is:  900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.
Item 2(c).  Citizenship.
PWAM is organized under the laws of the State of Delaware.  Mr. Park is a citizen of the United States.
Item 2(d).  Title of Class of Securities.
Common Stock, $0.001 par value per share.
Item 2(e).  CUSIP No.
269796108
Item 3.  If This Statement Is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
Not Applicable.

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 5 of 9 SEC Filing

Item 4.  Ownership.
 
(a)
Amount Beneficially Owned:
690,000*
         
 
(b)
Percent of Class:
4.4%*
         
 
(c)
Number of Shares as to which the person has:
  
         
   
(i)
sole power to vote or to direct the vote:
690,000*
         
   
(ii)
shared power to vote or to direct the vote
0
         
   
(iii)
sole power to dispose or to direct the disposition of:
690,000*
         
   
(iv)
shared power to dispose or to direct the disposition of
0
* This Schedule 13G is being jointly filed by (i) PWAM, a Delaware limited liability company and the investment manager to (a) PWIMF, a Cayman Islands exempted company that is the holder of  606,247 shares of Common Stock of the Company, as reported on this Schedule 13G, and (b) PWPI, a Cayman Islands exempted company that is the holder of 83,753 shares of Common Stock of the Company, as reported on this Schedule 13G; and (ii) Mr. Park, as the sole member and manager of PWAM.
The 690,000 shares of Common Stock held in the aggregate by the PW Funds, which constitute 4.4% of the shares of Common Stock deemed to be outstanding as of December 31, 2015, may be deemed to be beneficially owned (x) indirectly by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.  The foregoing beneficial ownership percentage is based upon 15,589,844 shares of Common Stock of the Company issued and outstanding as of November 10, 2015, based on information reported by the Company in its Quarterly Report on Form 10-Q for the fiscal year ended September 30, 2015, filed with the Securities and Exchange Commission on November 12, 2015.
Item 5.  Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  x

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 6 of 9 SEC Filing

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable.
Item 8.  Identification and Classification of Members of the Group.
Not Applicable.
Item 9.  Notice of Dissolution of Group.
Not Applicable.
Item 10.  Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 7 of 9 SEC Filing

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
January 21, 2016
  
     
 
/s/  Peter S. Park
  
 
Peter S. Park
    
         
         
 
PARK WEST ASSET MANAGEMENT LLC
  
         
 
By:
 /s/  Grace Jimenez  
   
Name:
Grace Jimenez
  
   
Title:
Chief Financial Officer
  
Attention:  Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001)

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 8 of 9 SEC Filing

Exhibit Index
Exhibit
Page
A.  Joint Filing Agreement, dated as of January 21, 2016, by and between Park West Asset Management LLC and Peter S. Park.
9

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Page 9 of 9 SEC Filing

Exhibit A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, $0.001 par value per share, of Eagle Pharmaceuticals, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as Exhibit A to such Schedule 13G.  In evidence thereof, the undersigned hereby execute this agreement this Twenty-First day of January, 2016.
 
/s/  Peter S. Park
  
 
Peter S. Park
  
       
       
       
 
PARK WEST ASSET MANAGEMENT LLC
  
       
 
By:
/s/    Grace Jimenez
  
   
Name: Grace Jimenez
 
   
Title: Chief Financial Officer
  

9

Follow Eagle Pharmaceuticals Inc. (OTC:EGRX)

Related Insider Monkey Articles
13G Filing: Luxor Capital Group and Sunedison, Inc. (SUNE)
13G Filing: Point72 Asset Management and POZEN Inc. (POZN)
13G Filing: Bridger Management and Chimerix Inc (CMRX)
13G Filing: Point72 Asset Management and DSW Inc. (DSW)
13G Filing: Saba Capital and Blackrock Debt Strategies Fund, Inc. (DSU)
13G Filing: Billionaire David Shaw's D. E. Shaw & Co. and AMAG Pharmaceuticals...